Get the Stockscreener App
293.72
0.69%
-2.04
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $293.72, with a volume of 1.64M.
It is down -0.69% in the last 24 hours and down -3.92% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$295.76
Open:
$295.49
24h Volume:
1.64M
Relative Volume:
0.69
Market Cap:
$158.13B
Revenue:
$34.76B
Net Income/Loss:
$6.62B
P/E Ratio:
24.02
EPS:
12.23
Net Cash Flow:
$10.61B
1W Performance:
-0.93%
1M Performance:
-3.92%
6M Performance:
-3.07%
1Y Performance:
-9.49%
1-Day Range:
$293.35
$297.89
1-Week Range:
$292.11
$301.47
52-Week Range:
$253.30
$339.17
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
293.72 | 157.54B | 34.76B | 6.62B | 10.61B | 12.23 |
|
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
FY2026 EPS Estimates for Amgen Boosted by Cantor Fitzgerald - MarketBeat
EverSource Wealth Advisors LLC Has $9.52 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Nations Financial Group Inc. IA ADV - MarketBeat
Amgen Inc. $AMGN is Sector Gamma AS's 5th Largest Position - MarketBeat
Amgen’s New Study on Tarlatamab and AB248: A Potential Game-Changer for Lung Cancer Treatment - TipRanks
Ex-Dividend Reminder: Amgen, U.S. Physical Therapy and Dynex Capital - Nasdaq
Amgen’s AMG-410 is pan-KRAS inhibitor - BioWorld MedTech
RWA Wealth Partners LLC Purchases 2,270 Shares of Amgen Inc. $AMGN - MarketBeat
Edgar Lomax Co. VA Sells 9,305 Shares of Amgen Inc. $AMGN - MarketBeat
Corient IA LLC Purchases New Holdings in Amgen Inc. $AMGN - MarketBeat
Brooklyn Investment Group Purchases 1,775 Shares of Amgen Inc. $AMGN - MarketBeat
Northern Trust Corp Lowers Stake in Amgen Inc. $AMGN - MarketBeat
Dimensional Fund Advisors LP Has $940.99 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Ethic Inc. - MarketBeat
3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade - The Motley Fool
Sei Investments Co. Purchases 4,282 Shares of Amgen Inc. $AMGN - MarketBeat
Waypoint Wealth Partners Inc. Purchases New Position in Amgen Inc. $AMGN - MarketBeat
Aberdeen Group plc Sells 126,680 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by American Investment Services Inc. - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Amgen Inc. $AMGN Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Freestone Capital Holdings LLC Has $3.63 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Seven Mile Advisory Acquires Shares of 891 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Steward Partners Investment Advisory LLC Has $23.04 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Cresset Asset Management LLC Decreases Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
How Amgen Inc. (AMGN) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Amgen: New Breakthroughs in Obesity, Rare Diseases, & High-Impact Therapies; But Is It Enough? - Smartkarma
FY2025 EPS Estimates for Amgen Lifted by Cantor Fitzgerald - MarketBeat
Rep. Lisa C. McClain Buys Amgen Inc. (NASDAQ:AMGN) Shares - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Stock Position Lifted by Raymond James Financial Inc. - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Philadelphia Trust Co. - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Brandywine Global Investment Management LLC - MarketBeat
GKV Capital Management Co. Inc. Sells 10,745 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Boston Partners - MarketBeat
Sienna Gestion Decreases Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Lowers Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Bought by Rathbones Group PLC - MarketBeat
Tokio Marine Asset Management Co. Ltd. Acquires 990 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Can Amgen Inc. continue delivering strong returnsMarket Sentiment Report & Free Community Consensus Stock Picks - thegnnews.com
E Fund Management Co. Ltd. Has $6.03 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Prudential PLC Decreases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
AIA Group Ltd Purchases Shares of 1,413 Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Precision Trading with Amgen Inc. (AMGN) Risk Zones - news.stocktradersdaily.com
Russell Investments Group Ltd. Reduces Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS - Benzinga
Amgen’s KRAS Mutation Study: A Potential Game-Changer in Colorectal Cancer Treatment - MSN
Amgen’s Evolocumab Study Completes: A New Era in Cardiovascular Prevention? - MSN
Amgen’s Promising Phase 2 Asthma Study: What Investors Need to Know - MSN
Amgen’s Sotorasib Study Update: Expanded Access for NSCLC Patients - MSN
Public Sector Pension Investment Board Purchases 5,732 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Jun 05 '25 |
Sale |
289.68 |
1,500 |
434,520 |
8,162 |
0.54%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):